Jim Cramer: Inovio Is a 'Really Speculative' Stock

Katherine Ross

Last night, on CNBC's Mad Money Jim Cramer talked to Robinhood's co-founder and co-CEO, Vlad Tenev. 

"Tenev said that Robinhood has been investing heavily to meet demand and rectify the service outages that occurred earlier this year. He said these are historic market conditions and Robinhood is seeing trading volumes up 300% from just a few months ago," wrote TheStreet's Scott Rutt. "Investors are adding more money to their Robinhood accounts and are buying and going long on stocks, Tenev explained. The top 10 stocks on their platform include pharmaceuticals and vaccine makers like Inovio Pharmaceuticals (INO) - Get Report and video conferencing companies."

And then, in his Real Money column on Tuesday morning, Cramer wrote about his takeaways from his interview with Tenev. 

"The most popular, why it's Inovio Pharmaceuticals. I always say own a speculative stock and the younger you are, the more speculative you can be. Inovio, which we have had on the show, is one of two companies in human trials for a vaccine for COVID-19. It's backed by the Bill and Melinda Gates Foundation. Its tests are going on at the University of Pennsylvania Hospital," wrote Cramer. 

 Read Cramer's thoughts here. 

And watch the full video above for Cramer's full take.

Want to know what Jim Cramer and his team at Action Alerts PLUS are thinking about the markets and the stocks they're watching? Sign up on Action Alerts PLUS for more.

Cramer and the team are weighing in on what members need to know about the coronavirus pandemic's impact on the market. Here's how you can recap his entire April show.

Watch More of the Latest Videos on TheStreet and Jim Cramer

Enter your email to register or login. Registration information may be shared with advertising partners in accordance with our Privacy Policy.